Neuphoria Therapeutics Inc. (NEUP) Form 10-Q — May 15, 2026
Neuphoria Therapeutics reported a net loss of $8.5 million for the nine months ended March 31, 2026, driven by the cessation of its core research and development activities following a failed Phase 3 trial for social anxiety disorder. The company has terminated all but one employee, paused its PTSD program, and is undergoing a strategic review to identify a potential buyer or partner. Despite the operational shutdown, Neuphoria maintains a cash position of $19.4 million, which management believes is sufficient to fund operations through the fourth quarter of fiscal 2027.
Key figures
- Revenue
- 0
- Total Debt
- 0
- Total Assets
- 34809200
- Cash Position
- 19440655
- Shares Outstanding
- 5404551
- Atm proceeds 9m
- 17915883
- G and a expense 9m
- 5681361
- R and d expense 9m
- 3965204
- Accumulated deficit
- 186894178
- Lynx1 bid per share
- 4.75
- Restructuring costs 9m
- 1278586
- Net cash used in ops 9m
- 13566928
Price after filing
Close on the filing date to close N calendar days later (from $5.09). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.